Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

NCT00875745 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00875745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00875745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
Indiana University
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
October 31, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, leukemia, promyelocytic, acute, myelodysplastic syndromes